

**PB 33 of 2024**

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 2) 2024

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following Determination.

Dated 23 April 2024

Nikolai Tsyganov

Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments—Additional designated brands effective from 1 August 2024 2

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023 2

Schedule 2—Amendments—Additional designated brands effective from 1 October 2024 3

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023 3

1 Name

 (1) This instrument is the *National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 2) 2024*.

 (2) This instrument may also be cited as PB 33 of 2024.

2 Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | The day after this instrument is registered. |  |
| 2. Schedule 1 | 1 August 2024. | 1 August 2024 |
| 3. Schedule 2 | 1 October 2024. | 1 October 2024 |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

 This instrument is made under subsection 99ADHC(2) of the *National Health Act 1953*.

4 Schedules

 Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments—Additional designated brands effective from 1 August 2024

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1 Section 5 (after table item dealing with the brand Penthrox of the drug Methoxyflurane in the form Liquid for inhalation 999 mg per g, 3 ml (with inhaler))

Insert:

|  |  |  |  |
| --- | --- | --- | --- |
| METOCLOPRAMIDE INJECTION BP | Metoclopramide | Injection containing 10 mg metoclopramide hydrochloride (as monohydrate) in 2 mL | Injection |

Schedule 2—Amendments—Additional designated brands effective from 1 October 2024

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1 Section 5 (before table item dealing with the brand PKU squeezie of the drug Amino acid formula with vitamins and minerals without phenylalanine in the form Oral gel 85 g, 30 (PKU squeezie)

Insert:

|  |  |  |  |
| --- | --- | --- | --- |
| GA gel | Amino acid formula with vitamins and minerals without lysine and low in tryptophan | Sachets containing oral powder 24 g, 30 (GA gel) | Oral |

2 Section 5 (after table item dealing with the brand Bicillin L-A of the drug Benzathine benzylpenicillin in the form Injection containing 600,000 units benzathine benzylpenicillin tetrahydrate in 1.17 mL single use pre-filled syringe)

Insert:

|  |  |  |  |
| --- | --- | --- | --- |
| Pulmicort Respules | Budesonide | Nebuliser suspension 500 micrograms in 2 mL single dose units, 30 | Inhalation |
| Pulmicort Turbuhaler | Budesonide | Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses | Inhalation by Mouth |

3 Section 5 (after table item dealing with the brand Triumeq of the drug Dolutegravir with abacavir and lamivudine in the form Tablet containing dolutegravir 50 mg with abacavir 600 mg and lamivudine 300 mg)

Insert:

|  |  |  |  |
| --- | --- | --- | --- |
| Sandrena | Estradiol | Transdermal gel 1 mg (as hemihydrate) in 1 g sachet, 28 | Transdermal |

4 Section 5 (after table item dealing with the brand Flucil of the drug Flucloxacillin in the form Powder for oral liquid 250 mg (as sodium monohydrate) per 5 mL, 100 mL)

Insert:

|  |  |  |  |
| --- | --- | --- | --- |
| Fucidin | Fusidic acid | Tablet containing sodium fusidate 250 mg | Oral |

5 Section 5 (after table item dealing with the brand Toujeo Solostar of the drug Insulin glargine in the form Injections (human analogue), cartridges, 300 units per mL, 1.5 mL, 5)

Insert:

|  |  |  |  |
| --- | --- | --- | --- |
| Isoleucine 1000 | Isoleucine with carbohydrate | Sachets of oral powder 4 g containing 1 g isoleucine, 30 (Isoleucine 1000) | Oral |
| Isoleucine 50 | Isoleucine with carbohydrate | Sachets of oral powder 4 g containing 50 mg isoleucine, 30 (Isoleucine 50) | Oral |

6 Section 5 (after table item dealing with the brand OsmoLax of the drug Macrogol 3350 in the form Powder for oral solution 510 g)

Insert:

|  |  |  |  |
| --- | --- | --- | --- |
| Provera | Medroxyprogesterone | Tablet containing medroxyprogesterone acetate 100 mg | Oral |
| Provera | Medroxyprogesterone | Tablet containing medroxyprogesterone acetate 200 mg | Oral |

7 Section 5 (after table item dealing with the brand Penthrox of the drug Methoxyflurane in the form Liquid for inhalation 999 mg per g, 3 ml (with inhaler))

Insert:

|  |  |  |  |
| --- | --- | --- | --- |
| Depo-Nisolone | Methylprednisolone | Injection containing methylprednisolone acetate 40 mg in 1 mL | Injection |

8 Section 5 (after table item dealing with the brand Stemetil of the drug Prochlorperazine in the form Injection containing prochlorperazine mesilate 12.5 mg in 1 mL)

Insert:

|  |  |  |  |
| --- | --- | --- | --- |
| DBL Promethazine Hydrochloride | Promethazine | Injection containing promethazine hydrochloride 50 mg in 2 mL | Injection |

9 Section 5 (after table item dealing with the brand Aptamil Gold+ Pepti-Junior of the drug Protein hydrolysate formula with medium chain triglycerides in the form Oral powder 450 g (Aptamil Gold+ Pepti-Junior))

Insert:

|  |  |  |  |
| --- | --- | --- | --- |
| Teglutik | Riluzole | Oral suspension 50 mg per 10 mL, 300 mL | Oral |

10 Section 5 (after table item dealing with the brand Micolette of the drug Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate in the form Enemas 3.125 g-450 mg-45 mg in 5 mL, 12)

Insert:

|  |  |  |  |
| --- | --- | --- | --- |
| Pfizer Australia Pty Ltd | Tobramycin | Injection 80 mg (as sulfate) in 2 mL (without preservative) | Injection |